FibroBiologics, Inc.
FBLG
$0.8762
$0.00120.14%
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 10.14% | -4.89% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 10.74% | 3.97% | |||
| Operating Income | -10.74% | -3.97% | |||
| Income Before Tax | -519.80% | -155.68% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -519.80% | -155.68% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -519.80% | -155.68% | |||
| EBIT | -10.74% | -3.97% | |||
| EBITDA | -10.59% | -3.98% | |||
| EPS Basic | -509.40% | -154.38% | |||
| Normalized Basic EPS | -510.75% | -154.07% | |||
| EPS Diluted | -509.40% | -154.38% | |||
| Normalized Diluted EPS | -510.75% | -154.07% | |||
| Average Basic Shares Outstanding | 1.82% | 2.44% | |||
| Average Diluted Shares Outstanding | 1.82% | 2.44% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
